Pawzmedi, a pet healthcare company, announced on the 4th that it has completed clinical trials for its pet body composition measuring device, ‘PawzScan’ (tentative name).
This clinical trial was conducted in collaboration with VetEngine, and FuzzScan showed high reliability at the level of DEXA (Dual Energy X-ray Absorptiometry). The body composition analysis results between FuzzScan and DEXA showed a very high correlation in whole body mass measurement, body fat mass and lean body mass measurement, body fat percentage and lean body mass measurement, etc. In the Bland-Altman analysis, the bias was close to 0 in whole body mass, body fat mass, and lean body mass items, and it was evaluated as a reliable measurement device.
Currently, the assessment of pet obesity mainly relies on the BCS (Body Consistency Score) evaluation method, but it is expected that the PuzzScan can be replaced as a more objective and precise body composition analysis device through this clinical trial. In particular, it is evaluated that it has a high possibility of being used as a body composition analysis device for veterinary hospitals and homes because it shows excellent performance in terms of cost-effectiveness and convenience compared to DEXA.
Fuzzymedi said it is aiming to launch Fuzzyscan in domestic and international animal hospitals and enter the global market in the second half of this year, and to this end, it is securing additional data to increase reliability and improving the product with user convenience in mind.
“The results of this clinical trial will bring about innovative changes in pet health management,” said Oh Je-woo, CEO of Puzmedi. “We plan to pursue commercialization, including additional research and related services, so that PuzScan can become an essential device for pets’ daily health management, including obesity prevention and muscle loss monitoring.”
You must be logged in to post a comment.